PML-IRIS During Fingolimod Diagnosed After Natalizumab Discontinuation

Case Reports in Neurological Medicine
doi 10.1155/2014/307872
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Hindawi Limited

Related search

Predictors for Multiple Sclerosis Relapses After Switching From Natalizumab to Fingolimod

Multiple Sclerosis
Neurology
2014English

Immune Reconstitution Inflammatory Syndrome in Natalizumab-Associated PML

Neurology
Neurology
2011English

Fingolimod-Associated PML in a Patient With Prior Immunosuppression

Neurology
Neurology
2016English

Natalizumab Versus Fingolimod and Dimethyl Fumarate in Multiple Sclerosis Treatment

Annals of Clinical and Translational Neurology
NeuroscienceNeurology
2018English

Immunological Markers for PML Prediction in MS Patients Treated With Natalizumab

Frontiers in Immunology
AllergyImmunology
2015English

Long-Term Evaluation of NEDA-3 Status in Relapsing-Remitting Multiple Sclerosis Patients After Switching From Natalizumab to Fingolimod

Therapeutic Advances in Neurological Disorders
NeurologyPharmacology
2018English

Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities

Multiple Sclerosis International
Neurology
2015English

Incomplete Susac Syndrome Exacerbated After Natalizumab

Neurology: Neuroimmunology and NeuroInflammation
Neurology
2015English

Efficacy of Natalizumab and Fingolimod in Relapsing Remitting Multiple Sclerosis in Real World Clinical Setting

Journal of Neurology & Neurophysiology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy